A B S T R A C T The ability to clone primary tumors in soft agar has proven useful in the study of the kinetics and biological properties of tumor stem cells. We report the development of an in vitro assay which permits formation of colonies of human monoclonal plasma cells in soft agar. Colony growth has been observed from bone marrow aspirates from 75% of the 70 patients with multiple myeloma or related monoclonal disorders studied. Growth was induced with either 0.02 ml of human type 0 erythrocytes or 0.25 ml of medium conditioned by the adherent spleen cells of mineral oil-primed BALB/c mice. 5 -500 colonies appeared after [2] [3] wk in culture yielding a plating efficiency of 0.001-0.1%. The number of myeloma colonies was proportional to the number of cells plated between concentrations of 105-106 and back-extrapolated through zero, suggesting that colonies were clones derived from single myeloma stem cells. Morphological, histochemical, and functional criteria showed the colonies to consist of immature plasmablasts and mature plasma cells. 60-80% of cells picked from colonies contained intracytoplasmic monoclonal immunoglobulin. Colony growth was most easily achieved from the bone marrow cells of untreated patients or those in relapse. Only 50% of bone marrow samples from patients in remission were successfully cultured. Tritiated thymidine suicide studies provided evidence that for most myeloma patients, a very high proportion of myeloma colony-forming cells was actively in transit through the cell cycle. Velocity sedimentation at 1 g showed myeloma stem cells sedimented in a broad band with a peak at 13 mm/h. Antibody to granulocyte colony-stimulating factor did not reduce the number or size of the colonies. Increased numbers of myeloma colonies were seen when the marrow was depleted of colony-stimulating INTRODUCTION Multiple myeloma has served as a valuable model neoplasm in both mouse and man (1) . Studies of myeloma immunoglobulin (M-component) synthesis and metabolism have been applied to quantitate the total body number of myeloma cells and to follow changes in tumor mass with treatment. Such serial tumor kinetic studies, and those of the tritiated thymidine labeling index of the tumor, have provided important insights on the kinetics of growth and regression of myeloma and on approaches to treatment (1, 2) . However, such studies do not directly assess the key compartment of the tumor, the tumor stem cells. Tumor stem cells provide the basic cell renewal system of the tumor, and are necessary to provide the colonizing property of a neoplasm capable of metastasis.
Usually, tumor stem cells have been assessed functionally in animals with various in vivo transplantation assays or with in vitro colony-forming assays. Such animal studies indicate that tumor stem cell assays can be used to study the properties of tumor stem cells and to delineate differences in individual sensitivities to chemotherapeutic agents (3) (4) (5) (6) . Furthermore, cloning systems (particularly those developed for culture of macrophage-granulocyte precursors) have proven ideal for the detection and characterization of regulatory factors controlling cell growth and differentiation (7) (8) (9) (10) .
Although primary explants of plasma cells in transplantable mouse myeloma have been successfully cloned in soft agar (4, 11, 12) , the in vitro cultivation of human plasma cells has met with little success (13) (14) (15) (16) for in vitro cultivation of mouse myeloma cells, Park (15) was able to culture human myeloma cells in soft agar. However, he was unable to establish linearity between numbers of cells plated and the number of colonies formed, and thus could not use this technique as an assay system. The lack of an in vitro bioassay for myeloma stem cells has hampered the study of the natural history of myeloma and the quantitation of myeloma stem cell mass.
This paper descirbes a useful in vitro bioassay for human myeloma colony-forming units in culture (M-cfu-c)1 which we have developed and applied successfully to the study of patients with multiple myeloma and related monoclonal bone marrow-derived (B)-cell neoplasms. Additionally, studies characterizing myeloma colony-forming cells and their growth requirements are reported.
METHODS
Patient studies. Patients with well-documented multiple myeloma, macroglobulinemia of Waldenstrom, or benign monoclonal gammopathy, and normal volunteers were selected for study. Detailed clinical and immunologic criteria for diagnosis and clinical staging of myeloma were as described previously (17) . Studies which are carried out routinely in our laboratory for case classification in monoclonal neoplasia include immunoelectrophoresis and immunoquantitation of serum and urine M-components, radioimmunoassay measurement of the in vitro synthetic rate of M-component by bone marrow plasma cells (2, 18) , and measurement of the tritiated thymidine ([3H]Tdr) labeling index of marrow plasma cells by the high-speed scintillation autoradiography technique (19) (20) . Immediately before use, 10 ml of 3% tryptic soy broth (Grand Island Biological Co.), 0.6 ml asparagine (0.6 mg/ml), and 0.3 ml DEAE-dextran (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) were added to 40 ml of the enriched medium.
The second feeder layer utilized 0.25 ml of conditioned medium in 0.5% agar and enriched McCoy's 5a medium. The conditioned medium was prepared from the adherent spleen cells of BALB/c mice which had been primed with 0.2 ml of mineral oil injected intraperitoneally 4 wk previously. This was based on a protocol of Namba and Hanoka for in vitro cultivation of mouse myeloma cells (21) . The adherent spleen cells were obtained as follows: the spleens were teased with needles to form a single cell suspension, and 5 x 106 cells were placed in 60-mm Falcon tissue culture dishes in RPMI 1640 medium (Grand Island Biological Co.) containing 20% horse serum. A 2-h incubation was used to permit cellular adherence. Subsequently, the dishes were rinsed three times in cold phosphatebuffered saline. Cells were then incubated for 3 days at 37°C in 5 ml ofRPMI 1640 with 15% heat-inactivated fetal calf serum, penicillin (100 U/ml), streptomycin (2 mg/ml), and glutamine (2 mM). The conditioned medium was decanted and centrifuged at 400 g for 20 min. The supernate was passed through a 0.45-,um Nalgene filter (Nalge Co., Nalgene Labware Div., Rochester, N. Y.) and stored up to 1 mo at -20°C.
Bone marrow cells to be tested were suspended in 0.3% agar in CMRL 1066 medium (Grand Island Biological Co.) supplemented with 20% horse serum, penicillin (100 U/ml), streptomycin (2 mg/ml), glutamine (2 mM), CaCl2 (4 mM), insulin (3 U/ml), asparagine (0.6 mg/ml), and DEAEdextran (0.5 mg/ml) to yield a final concentration of 5 x 105 cells/ml. Freshly prepared 2-mercaptoethanol was added at a concentration of 50 AM immediately before plating the cells (22) . 1 ml of the resultant mixture was pipetted onto the 1-ml feeder layer. Cultures were incubated at 37°C in 5% CO2 in a humidified atmosphere with no additional feeding. Cultures were examined in an inverted phase microscope at x 100 and 200.
Final colony counts were made 14-21 days after plating. Inasmuch as cultures containing erythrocytes were quite opaque, erythrocyte lysis was completed by addition of 0.5 ml of 3% acetic acid as necessary before scoring.
Examination of cells in colonies. Individual colonies were removed from the dish using a fine capillary pipette and were suspended in a drop of heat-inactivated fetal calf serum. Colonies were air-dried 3-4 h. Cells were stained routinely with Wright-Giemsa, 0.5% orcein in 60% acetic acid, peroxidase (23) , and methyl green pyronin (24) . Cell separation by velocity sedimentation. Cell suspensions were separated by velocity sedimentation at unit gravity using the Staput method of Miller and Phillips (26) . This technique separates cells primarily on the basis of size. Briefly, 1 x 108 cells, suspended in phosphate-buffered saline with 5% fetal calf serum were sedimented through a 15-30% fetal calf serum gradient in a cylindrical siliconized glass chamber 18 cm in diameter (Johns Scientific Co., Toronto, Ontario, Canada). Sedimentation was carried out at 4°C for 150 min, and the chamber was then drained. The first 250 ml, consisting of the fluid in the conical portion of the chamber, was discarded. The remainder of the gradient was collected in 50-ml fractions. Cells were centrifuged at 150g for 10 min and washed. Nucleated cell counts for each fraction were made in a hemocytometer after dilution in 3% acetic acid, and cytocentrifuge preparations were made.
Preparation of nonadherent and nonphagocytic cell populations. Freshly washed bone marrow cells were further separated into adherent and nonadherent populations by the method of Messner et al. (27) . Briefly, cells were allowed to adhere for 30 (Fig. 1A) as opposed to loosely aggregated cells in contaminating granulocyte colonies. Growth kinetics of human myeloma cells in agar were similar to those described by Park (15) . 
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A. Hamburger and S. E. Salmon The number of myeloma colonies ranged from 5 to 500 per plate, yielding a cloning efficiency of 0.001-0.1%. A linear relationship was obtained between the number of nucleated cells plated and the number of colonies found after 21 days (Fig. 2) . The plot could be back-extrapolated through zero, suggesting colony origin from a single cell.
Cells from individual colonies when plucked from agar appeared to be plasma cells when examined by light microscopy after staining with Wright-Giemsa or methyl green pyronin (Fig. 1B) . In Wright-Giemsastained preparations, the day 5-8 colonies were composed of a population of large mononuclear cells with bulky basophilic cytoplasm. However, colonies from older cultures contained mature plasma cells.
Cells were peroxidase-negative and incapable of phagocytosis of neutral red or latex particles. Immunofluorescent studies demonstrated that 60-80% of the myeloma cells of individual colonies had the cytoplasmic immunofluorescence specific for the monoclonal immunoglobulin present in the serum of the patient studied (Fig. 1C) .
To study the cell renewal capability of the M-cfu-c, serial replating studies were carried out on myeloma colony plates from one patient (R. B.). In serial experiments, clusters and colonies of 2-, 5-, and 8-day incubations were plucked from the agar with a micropipette. The harvest of a given day was pooled, resuspended in medium, and passed through a 23-gauge needle for dispersion. The resulting singlecell suspension was then replated at 5 x 105 cells per plate over a fresh feeder layer. Despite the potential disruption and stem cell death which can result from such transfer experiments, clusters and colonies harvested as described above were capable of forming secondary myeloma colonies in the range of 100 colonies per plate, indicating some preservation of the primary colony-forming units in the culture system. In companion studies, washed cells plucked from myeloma colonies were incubated for varying times up to 24 h at 37°C in suspension culture along with tritiated leucine. The supernatant culture fluid from these cultures was then subjected to the solid-phase radioimmunoassay for intrinsically labeled IgG standardized in our laboratory (18) . Cells from myeloma colonies were found to be capable of secreting IgG in quantities quite similar to myeloma cells from bone marrow samples (1, 2) . The myeloma colonies were therefore operationally defined as arising from myeloma stem cells. Sedimentation velocity analysis of M-cfu-c. The sedimentation velocity of M-cfu-c was determined using the Staput apparatus. A representative experiment using bone marrow cells from an untreated myeloma patient is depicted in Fig. 3 . Three additional experiments with cells from other myeloma patients have yielded similar results. In contrast to the nucleated cell profile obtained from normal bone marrow (28) , myeloma bone marrow contained a large population of rapidly sedimenting cells. Myeloma stem cells sedimented as a single broad band with a peak sedimentation velocity of 13 mm/h. This value is in good agreement with that of Park who reported that M-cfu-c sedimented at 12 mm/h (15) .
In an additional experiment, marrow cells from a second myeloma patient were separated on a Staput gradient, after which fractions were split, and cells were plated in either a granulocyte culture assay or the myeloma culture system. The number of granulocyte (G-) or M-cfu-c were evaluated in each fraction. The results are shown in Fig. 4 . G-cfu-c sedimented much more slowly than M-cfu-c. There were approximately 10 times as many G-cfu-c in this marrow as M-cfu-c. Effect of depletion of phagocytic or adherent cells. Although no exogenous source of colony-stimulating factor (CSF) is supplied in our culture system, adherent phagocytic cells of the bone marrow produce endogenous CSF that permits granulocyte growth (29) . Therefore, bone marrow suspensions were depleted 15 of either adherent or phagocytic cells, or both populations, before plating. In every case (Table V) The nature of the potentiating effect of either erythrocytes or conditioned medium requires much further analysis. Metcalf (11, 12) has reported that intact mouse erythrocytes potentiated growth of murine plasmacytomas in vitro. However, this activity was lost when erythrocytes were lysed. In contrast, lysates of human erythrocytes supported myeloma cell growth. This might suggest that a different mechanism is involved in the potentiation of human plasma cell growth. Whether the factor(s) provided by erythrocytes and conditioned medium were similar remains to be determined.
In addition, the role of 2-mercaptoethanol remains unclear, although its helper effect in a variety of immunological reactions (31) and a clonal assay for mouse B lymphocytes has been well documented (22) . It is possible that mercaptoethanol substitutes for a specific metabolite or induces the formation of a growth regulator in a fashion analogous to its promotion of release of CSF from lymphoid cells (32 serum was prompted by reports of Park et al. (4) that high levels of fetal calf serum inhibited in vitro growth of murine plasmacytomas. We have noted a similar effect of fetal calf serum on human M-cfu-c growth. The use of human serum was avoided to minimize growth of granulocyte colonies (33) .
We believe our in vitro technique will be useful in studying the growth kinetics of human myeloma. Prior studies from our laboratory have shown that the total body tumor mass in myeloma is in the range of 1012 cells at the time of diagnosis, with death occurring after two to three more doublings in total body tumor burden. Assuming that our in vitro colony assay does measure myeloma stem cells, then (based on our highest plating efficiencies of 0.2%) the minimum number of myeloma cells in the tumor stem cell compartment is in the range of 109 at the time of diagnosis. Our [3H]Tdr suicide studies suggest that in most patients a very high proportion of M-cfu-c are in the cell cycle. If we assume that the total cell cycle duration is equal to twice the S-phase duration, then it would appear that the median fraction of myeloma stem cells in cycle in the patients studied was 72%. Of interest, there was no reduction in the number of M-cfu-c with [3H]Tdr suicide in the two patients studied who had the highest concentrations of myeloma cells in the bone marrow (73 and 90% (2) . Our in vitro colony-forming studies now provide independent evidence that when human myeloma stem cells are present in low cell concentrations, growth can proceed rapidly. It was of interest to observe that monoclonal colonies from macroglobulinemia and benign monoclonal gammopathy grew with equal vigor. Although we studied few cases, we speculate that differences in the in vivo environment or feedback regulation could account for the more indolent clinical behavior of those two neoplasms. Additional studies will be necessary to further assess plasma cell colony growth patterns in these latter disorders.
In addition to clarifying the cellular kinetics of myeloma, it appears that such assays will prove to have clinical importance. Specifically, in vitro tumor colony-forming assays have been used for detailed studies of drug and radiation sensitivity ofmouse myeloma stem cells and have been predictive of in vivo results (6) . In preliminary experiments, we have observed individual differences in sensitivity of human M-cfu-c from different patients to melphalan, 1,3-bis(2-chloroethyl)-1-nitrosourea, and doxorubicin hydrochloride. Previous studies from our laboratory relating total tumor mass staging to response to treatment and survival (17) suggested that tumor mass per se, while predictive of survival, was only of modest value in prediction of response to treatment. At that time we conjectured that the major measured predictive factor was drug sensitivity itsel£. Individualized studies of drug sensitivity of myeloma colonies may therefore have potential use for predictive cancer chemotherapy of multiple myeloma. We have now initiated a study to determine, both retrospectively and prospectively, if the in vitro survival of a patient's cells to drugs correlates with the clinical response to chemotherapy. A large number of such observations will be necessary to determine if the technique will be of value in predicting patients' response to treatment.
